Investment Ratings
As per analysts rating in the last 6 months, the recommendation is to HOLD Indoco Remedies
-
Master Rating:
-
Indoco Remedies has an operating revenue of Rs. 1,411.05 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 11% is healthy, ROE of 12% is good. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 146 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indoco Remedies Ltd Forecast
Price Estimates
Eps And Sales Estimates
Indoco Remedies Ltd Synopsis
NSE-Medical-Diversified
Indoco Remedies is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1240.30 Cr. and Equity Capital is Rs. 18.43 Cr. for the Year ended 31/03/2021. Indoco Remedies Ltd. is a Public Limited Listed company incorporated on 23/08/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L85190MH1947PLC005913 and registration number is 005913.-
Market Cap
INR 3,715.49 Cr
-
Sales
INR 1,409.87 Cr
-
Shares in Float
3.78 Cr
-
No of Funds
67 K
-
Yield
0.38%
-
Book Value
4.76
-
U/D Vol Ratio
0.5
-
LTDebt/Equity
13%
-
Alpha
0.07
-
Beta
0.82
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 58.54% | 58.69% | 58.69% |
| Mutual Funds | 18.62% | 18.74% | 16.69% |
| Insurance Companies | 0.13% | 0.13% | 0.14% |
| Foreign Portfolio Investors | 2.29% | 2.66% | 2.88% |
| Individual Investors | 16.13% | 15.92% | 17.07% |
| Others | 4.29% | 3.86% | 4.53% |
| Name | Designation |
|---|---|
| Mr. Suresh G Kare | Chairman |
| Ms. Aditi Panandikar | Managing Director |
| Mr. Sundeep V Bambolkar | Joint Managing Director |
| Dr. Anand Nadkarni | Non Executive Director |
| Mr. D M Gavaskar | Independent Director |
| Mr. Rajiv P Kakodkar | Independent Director |
| Dr.(Ms.) Vasudha V Kamat | Independent Director |
| Mr. Abhijit Y Gore | Independent Director |
Indoco Remedies Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 386.59 | 386.49 | 294.81 | 333.31 | 327.65 |
| Operating Expenses Qtr Cr | 300.27 | 299.68 | 250.28 | 271.98 | 267.47 |
| Operating Profit Qtr Cr | 86.32 | 86.81 | 54.57 | 59.96 | 60.18 |
| Depreciation Qtr Cr | 19.46 | 22.23 | 18.54 | 16.88 | 18.57 |
| Interest Qtr Cr | 3.06 | 4.23 | 4.55 | 6.03 | 5.89 |
| Tax Qtr Cr | 23.24 | 21.6 | 8.54 | 12.28 | 11.13 |
| Net Profit Qtr Cr | 41.57 | 39.61 | 24.91 | 25.14 | 25.11 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 1243.4151 | 1108.4247 | 973.888 | 1043.0029 | 1076.1932 |
| Operating Expenses Annual Cr | 1016.7278 | 982.6529 | 891.0285 | 903.3635 | 915.4319 |
| Operating Profit Annual in Cr | 223.5751 | 123.342 | 76.7048 | 134.8501 | 156.6256 |
| Depreciation Cr | 73.1205 | 70.8112 | 71.5641 | 67.7058 | 63.2652 |
| Interest Annual Cr | 22.2164 | 26.252 | 20.5389 | 23.5074 | 6.1604 |
| Tax Annual Cr | 38.9584 | 4.4604 | -6.4024 | 7.2305 | 13.8799 |
| Net Profit Annual Cr | 92.392 | 24.2482 | -2.8411 | 41.1957 | 77.4558 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 82.174 | 122.6554 | 132.1337 | 122.7602 | 87.807 |
| Cash from Investing Activity Annual Cr | -66.6969 | -55.9466 | -103.7573 | -135.4301 | -170.5372 |
| Cash from Financing Annual Activity Cr | -29.8279 | -63.947 | -16.1424 | -38.7658 | 132.3967 |
| Net Cash Flow Annual Cr | -14.3508 | 2.7618 | 12.234 | -51.4357 | 49.6665 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 768.9288 | 680.1611 | 661.0832 | 675.5588 | 651.8795 |
| Fixed Assets Annual Cr | 638.0133 | 640.3206 | 652.9502 | 624.2851 | 530.3817 |
| Total Non Current Assets Annual Cr | 694.6194 | 710.5462 | 721.7959 | 700.8463 | 627.057 |
| Total Current Assets Annual Cr | 621.9485 | 561.764 | 536.5038 | 537.1519 | 570.1785 |
| Total Assets Annual Cr | 1316.5679 | 1272.3102 | 1258.2997 | 1237.9982 | 1197.2355 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 83.4426 | 73.8098 | 71.7394 | 73.3102 | 70.7406 |
| ROE Annual % | 12.01 | 3.56 | -0.42 | 6.09 | 11.88 |
| ROCE Annual % | 16.91 | 6.75 | 1.38 | 8.76 | 12.08 |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 18.27 | 11.37 | 8.56 | 13.44 | 14.99 |
Indoco Remedies Ltd Technicals
EMA & SMA
CURRENT PRICE
402.05 
(1.16)
-
- Bullish Moving Averages 6
- Bearish Moving Averages 10
EMA
-
20 Day
413.1
-
50 Day
431.87
-
100 Day
428.27
-
200 Day
394.81
Indoco Remedies Ltd Resistance and support
392.82 PIVOT
-
First Resistance
406.64
-
Second Resistance
415.82
-
Third Resistance
429.64
-
First Support
383.64
-
Second Support
369.82
-
Third Support
360.64
-
RSI
39.26
-
MFI
35.84
-
MACD
-15.93
-
MACD signal line
-14.44
Indoco Remedies Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 230,351 | 7,090,204 | 30.78% |
| Week | 194,897 | 8,425,389 | 43.23% |
| 1 Month | 183,242 | 8,458,444 | 46.16% |
| 6 Month | 493,777 | 13,514,668 | 27.37% |
Indoco Remedies Ltd Price change analysis
-55.2
Over 1 month
Low High 376.35 466.9
-84.25
Over 3 month
Low High 376.35 513.65
5.5
Over 6 months
Low High 376.35 530.25
118.6
Over Year
Low High 251.9 530.25Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Lasa Supergenerics Ltd | 100.15 | 63.30 (0.32%) | 10590 |
| Morepen Laboratories Ltd | 75.00 | 52.90 (3.73%) | 559595 |
| Wockhardt Ltd | 804.50 | 442.15 (2.56%) | 58370 |
| IOL Chemicals & Pharmaceuticals Ltd | 807.30 | 450.10 (-0.98%) | 28789 |
News
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulatio
Intimation of Schedule of Analyst / Institutional Investors Meet Read More
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulatio
Intimation of Schedule of Analyst / Institutional Investors Meet Read More
INDOCO REMEDIES LTD. - 532612 - Related Party Transactions P
Related party transactions pursuant to Reg 23(9) of SEBI (LODR) Reg, 2015 (Listing Regulations) Read More
Accumulate Indoco Remedies; target of Rs 480: Prabhudas Lill
Prabhudas Lilladher recommended accumulate rating on Indoco Remedies with a target price of Rs 480 in its research report dated November 04, Read More
INDOCO REMEDIES LTD. - 532612 - Audio Recording Of Conferenc
Audio recording of Conference Call held on November 02, 2021 Read MoreBlogs